These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 37529398)

  • 1. Combined approaches for increasing fetal hemoglobin (HbF) and
    Finotti A; Gambari R
    Front Genome Ed; 2023; 5():1204536. PubMed ID: 37529398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
    Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β
    Cosenza LC; Gasparello J; Romanini N; Zurlo M; Zuccato C; Gambari R; Finotti A
    Mol Ther Methods Clin Dev; 2021 Jun; 21():507-523. PubMed ID: 33997100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
    Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
    Elife; 2022 Feb; 11():. PubMed ID: 35147495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Fetal Hemoglobin by Introducing Natural Hereditary Persistence of Fetal Hemoglobin Mutations in the γ-Globin Gene Promoters for Genome Editing Therapies for β-Thalassemia.
    Lu D; Xu Z; Peng Z; Yang Y; Song B; Xiong Z; Ma Z; Guan H; Chen B; Nakamura Y; Zeng J; Liu N; Sun X; Chen D
    Front Genet; 2022; 13():881937. PubMed ID: 35656314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Erythroid Precursor Cells from β-Thalassemia Patients with
    Zuccato C; Cosenza LC; Zurlo M; Lampronti I; Borgatti M; Scapoli C; Gambari R; Finotti A
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
    Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
    Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of therapeutic levels of HbF in genome-edited primary β
    Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
    Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
    Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
    Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis.
    Quagliano A; Acevedo D; Hardigan P; Prasad S
    Front Med (Lausanne); 2022; 9():943631. PubMed ID: 36250099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome editing approaches to β-hemoglobinopathies.
    Brusson M; Miccio A
    Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression analysis data of BCL11A and γ-globin genes in KU812 and KG-1 cell lines after CRISPR/Cas9-mediated BCL11A enhancer deletion.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Buch T; Karimipoor M
    Data Brief; 2020 Feb; 28():104974. PubMed ID: 31890812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies.
    Venkatesan V; Christopher AC; Rhiel M; Azhagiri MKK; Babu P; Walavalkar K; Saravanan B; Andrieux G; Rangaraj S; Srinivasan S; Karuppusamy KV; Jacob A; Bagchi A; Pai AA; Nakamura Y; Kurita R; Balasubramanian P; Pai R; Marepally SK; Mohankumar KM; Velayudhan SR; Boerries M; Notani D; Cathomen T; Srivastava A; Thangavel S
    Mol Ther Nucleic Acids; 2023 Jun; 32():671-688. PubMed ID: 37215154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.
    Demirci S; Leonard A; Essawi K; Tisdale JF
    Mol Ther Methods Clin Dev; 2021 Dec; 23():276-285. PubMed ID: 34729375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir induces fetal hemoglobin via downregulation of γ-globin repressors, BCL11A and SOX6 trans-acting factors.
    Ali H; Khan F; Ghulam Musharraf S
    Biochem Pharmacol; 2021 Aug; 190():114612. PubMed ID: 34010599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
    Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
    Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
    Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
    Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.